SCHEMBL1150503

SCHEMBL1150503

COc1cnc2c(ccn2-c2ccccc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 4/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
MAPK10 P53779 1/20 0.44
NCOA1 Q15788 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
PTK2 Q05397 5/20 0.42
KDR P35968 2/20 0.42
AURKA O14965 2/20 0.42
ABL1 P00519 2/20 0.42
DAPK3 O43293 1/20 0.42
JAK2 O60674 1/20 0.42
PAK4 O96013 1/20 0.42
NTRK1 P04629 1/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
CSF1R P07333 1/20 0.42
RET P07949 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28543131 0.76 ENPP3 (0.47) FGFR1HPGDMAPK1KDRAURKA
SCHEMBL8133385 0.76 APP (0.41) ALDH1A1HPGDCLK4NPC1RAB9A
SCHEMBL23675313 0.75 PTPN11 (0.51) FGFR1HPGDPTK2KDRAURKA
SCHEMBL14217528 0.74 ROCK1 (0.38) ALDH1A1HPGDNPC1RAB9AMAPT
SCHEMBL1683418 0.73 HTR6 (0.62) FGFR1ALDH1A1HPGDHTTMET
SCHEMBL1144469 0.73 FGFR1 (0.55) FGFR1ALDH1A1HPGDMAPK1HTT
SCHEMBL27296926 0.73 IRAK4 (0.39) FGFR1HPGDMAPK1KDRAURKA
SCHEMBL23327801 0.73 SLC22A12 (0.41) ALDH1A1HPGDPDGFRBPDGFRAMAPT
SCHEMBL27296922 0.73 CYP19A1 (0.41) PTK2
SCHEMBL23675298 0.72 PTK2 (0.50) FGFR1ALDH1A1HPGDMAPK1PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580813-B2 Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals SANOFI (FR) 2013-11-12 US disclosed
EP-2240482-B1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-07-17 EP disclosed
US-20110039861-A1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2011-02-17 US disclosed
EP-2240482-A1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2010-10-20 EP disclosed
WO-2009095162-A1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039861-A1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS REN, PM20D2, CDK20 FGFR1 2590/4885ALDH1A1 2609/4885HPGD 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.